Compare Vanguard S&P 500 Growth Index Fund ETF (VOOG) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard S&P 500 Growth Index Fund ETF vs 22nd Century Group Inc — how do they compare? Vanguard S&P 500 Growth Index Fund ETF trades at $83.6, while 22nd Century Group Inc trades at $2.12 (market cap $1.62M). The key difference: Vanguard S&P 500 Growth Index Fund ETF is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals.
| VOOG | XXII | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $85.69 | $594.00 |
52-Week Low | $65.32 | $2.13 |
Market Cap | — | $1.62M |
Enterprise Value | — | -$2.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VOOG trades at $84.08, down 0.5% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF focuses on S&P 500 growth stocks, offering exposure to large-cap leaders with a low expense ratio of 0.07% (Vanguard, 2026). Recent news highlights strong long-term performance, including over 400% total returns in the past decade (The Motley Fool, 2026-09-07).
Outlook remains positive for growth-oriented investors, supported by institutional buying and media optimism. Key risks include tech sector concentration and market volatility. Analysts favor VOOG for its cost efficiency and historical outperformance, though valuation sensitivity persists amid economic uncertainties.
XXII trades at $2.29, down 4.58% today, showing continued bearish momentum with negative technical signals. The company faces severe financial challenges with negative profit margins (-76.01% net income margin) and consecutive earnings misses. Despite analyst optimism (75% buy ratings), fundamental weakness persists with declining revenue and substantial losses. Recent corporate actions include a 20:1 reverse stock split completed June 2026 to maintain listing compliance.
The outlook remains challenging given persistent operational losses and negative cash flow from operations. Investment opportunity exists if the company can capitalize on its claimed $50B market opportunity and improve gross margins. Key risks include continued cash burn, competitive pressures in tobacco alternatives, and execution challenges in commercializing VLN products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
